Business Wire

CA-VEEVA-SYSTEMS

11.6.2019 22:07:06 CEST | Business Wire | Press release

Share
2019 Veeva R&D Summit Europe to Showcase Advances for Speeding Product Development

Veeva Systems (NYSE:VEEV):

What:

Veeva Systems (NYSE:VEEV) will host the 2019 Veeva R&D Summit, Europe for more than 600 life sciences professionals and industry experts from over 145 companies registered to attend, making it the largest Veeva R&D Summit in Europe to date. Keynotes and breakout sessions will showcase the latest advancements for unifying systems and processes in clinical, regulatory, and quality for faster product development.

Keynote Speakers:

  • Dr. Jacques Mascaro, senior vice president and head of regulatory affairs and R&D quality at the Healthcare business of the Merck Group
  • Professor Mike Stroud OBE, explorer and expert on human health under extreme conditions who is recognized for his record-breaking expeditions with Sir Ranulph Fiennes
  • Chris Moore, president of Veeva Europe

Sessions and Themes:

The event will offer 34 sessions with more than 50 speakers, including leading global pharmaceutical companies and emerging biotechs such as Bayer, Horizon, and UCB. Featured sessions on optimizing trial performance, modernizing quality management, and transforming regulatory operations include:

  • AstraZeneca sharing best practices for modernizing clinical operations and streamlining trial execution with a unified suite of applications.
  • Novo Nordisk explaining how they modernized and simplified a fragmented system landscape for controlled content management – eliminating IT risks and gaining greater business value.
  • GE Healthcare discussing lessons learned in regulatory transformation, from improving the planning process to streamlining cross-functional business processes and measuring success.

When:

11-13 June in Barcelona, Spain

Where:

Garden Level Palau de Congressos de Catalunya

Sponsors:

2019 Veeva R&D Summit, Europe is sponsored by Accenture, NNIT, Valiance, CGI, Eagle Productivity Solutions, Ernst & Young, fme AG, PwC Germany, SDL, BASE life science, Deloitte, Epista Life Sciences, Ideagen, INCONSULT, Kinapse, and LPW Training.

Who:

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 750 customers, including 430+ Veeva Development Cloud customers, 265+ Vault Clinical customers, 180+ Vault RIM customers, 220+ Vault Quality customers, and 180+ customers using multiple Veeva Vault applications. Veeva customers range from emerging biotechs to the world’s top 20 largest biopharmaceutical companies, including Vault Clinical (12 of top 20), Vault RIM (7 of top 20), and Vault Quality (10 of top 20). Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2019. This is available on the company’s website at veeva.com  under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc. Veeva Systems Inc. owns other registered and unregistered trademarks.

Contact:

Roger Villareal Veeva Systems 925-264-8885 roger.villareal@veeva.com

Kiran May Veeva Systems +44-796-643-2912 kiran.may@veeva.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release

Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor

PUMA and Salehe Bembury Host Immersive Sound-Inspired Experience ahead of Football’s Biggest Tournament at The Row DTLA5.6.2026 09:59:00 CEST | Press release

Event Celebrated the launch of the PUMA x Salehe Bembury TRVL WEAR Collection and Velum 1 to be worn by PUMA’s 11 Federations this summer Global sports company PUMA and visionary designer Salehe Bembury hosted an immersive experience at The Row DTLA celebrating their collaboration ahead of football's biggest global tournament. The activation transformed the historic venue into a series of interactive environments, offering guests an inside look into the creative world behind the partnership. Set against the backdrop of Los Angeles, the event brought football beyond the pitch and into everyday life through the lens of sound and design. The PUMA x SALEHE BEMBURY collaboration kicks off PUMA’s second chapter of football introductions this summer, following the launch of their 11 national federation kits in March. This more streetwear-oriented launch introduces a bespoke collection of travel wear and goalkeeper kits for PUMA’s 11 national federations in the tournament. This press release f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye